Tonix Pharmaceuticals Holding Corp.
TNXP
$12.87
-$0.29-2.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 577.88% | 183.16% | 108.75% | 16.58% | -9.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 577.88% | 183.16% | 108.75% | 16.58% | -9.51% |
| Cost of Revenue | -78.51% | 67.34% | -10.57% | -12.09% | -2.82% |
| Gross Profit | 1,107.93% | 256.66% | 209.65% | 51.78% | -9.92% |
| SG&A Expenses | 121.94% | 183.29% | 128.96% | 233.48% | 115.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.12% | 161.94% | 114.17% | 97.85% | 47.29% |
| Operating Income | -50.32% | -158.73% | -114.80% | -112.59% | -54.13% |
| Income Before Tax | -43.44% | -138.84% | -112.19% | -125.22% | 64.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.44% | -138.84% | -112.19% | -125.22% | 64.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.44% | -138.84% | -112.19% | -125.22% | 64.11% |
| EBIT | -50.32% | -158.73% | -114.80% | -112.59% | -54.13% |
| EBITDA | -50.71% | -163.36% | -117.42% | -124.19% | -59.35% |
| EPS Basic | 36.82% | -3.28% | 59.29% | 84.18% | 99.80% |
| Normalized Basic EPS | 36.82% | -17.93% | 59.29% | 84.18% | 99.20% |
| EPS Diluted | 36.82% | -3.28% | 59.29% | 84.18% | 99.80% |
| Normalized Diluted EPS | 36.82% | -17.93% | 59.29% | 84.18% | 99.20% |
| Average Basic Shares Outstanding | 127.03% | 131.26% | 421.27% | 1,323.78% | 17,771.46% |
| Average Diluted Shares Outstanding | 127.03% | 131.26% | 421.27% | 1,323.78% | 17,771.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |